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Abstract 19 
Liposomes have been the centre of attention in research due to their potential to act as drug 20 
delivery systems. Although its versatility and manufacturing processes are still not scalable and 21 
reproducible. In this study, the microfluidic method for liposomes preparation is presented. 22 
DMPC and DSPC liposomes containing two different lipid/cholesterol ratios (1:1 and 2:1) are 23 
prepared. Results from this preparation process were compared with the film hydration method 24 
in order to understand benefits and drawbacks of microfluidics. Liposomes characterisation 25 
was evaluated through stability studies, encapsulation efficacy and drug release profiles of 26 
hydrophilic and lipophilic compounds. Stability tests were performed during 3 weeks and the 27 
liposomes properties of the most stable formulations were determined using Infrared 28 
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Microscopy and Atomic Force Microscopy. Microfluidic allows loading of drugs and assembly 29 
in a quick single step and the chosen flow ratio for liposomes formulation plays a fundamental 30 
role for particle sizes. One hydrophilic and one lipophilic compound were incorporated 31 
showing how formulation and physic-chemical characteristics can influence the drug release 32 
profile. 33 
Keywords: liposomes, microfluidics, encapsulation efficacy, controlled release. 34 
 35 
1. Introduction 36 
Liposomes are lipid structures that can be self-assembled naturally or prepared with natural or 37 
synthetic lipids [Immordino et al., 2006; Yadav et al., 2011]. These molecules present an 38 
amphipathic environment, which allows hydrophobic and hydrophilic drugs incorporation, 39 
thus providing an excellent structure for drug delivery systems [Immordino et al., 2006; Pattni 40 
et al., 2015]. The stability of the liposomal product depends on chemical, physical, and 41 
biological properties. Changes can occur during storage and modify important features 42 
correlated to the drug delivery process. Chemical transformations for example can influence in 43 
vivo fate of the liposome by affecting its loading and releasing properties [Heurtault, 2003].  44 
Liposome production aims to achieve predictable and reproducible particle size distributions 45 
[Kreuter, 1994]. Commonly used methods for liposome formulation include hydration of lipids 46 
in aqueous buffer, freeze-thaw cycling, film hydration, reversed phase evaporation, normal 47 
phase integration, detergent depletion, and pH adjustment [Jahn et al., 2007]. All of these are 48 
conducted through the mixing of bulk phases. Traditional bulk methods of preparing liposomes 49 
are often characterised by heterogeneous and poorly controlled chemical and/or mechanical 50 
conditions that often result in liposomes poly-disperse in size and lamellarity [Jahn et al., 2004, 51 
2007].  52 
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Due to these difficulties, microfluidics techniques overcome reproducibility problems. They 53 
work with small volume of fluids (10±9 to 10±8 litres) within channels with dimensions of  10 54 
to 100 micrometres [Whitesides, 2006]. Many advantages come with usage of these techniques, 55 
such as more thoughtful use of sample and reagent resources, possibility to carry out 56 
separations and detections with higher resolution and sensitivity, lower cost of the whole 57 
procedure, quicker analysis, and small footprints for the analytical devices [Squires and Quake, 58 
2005; Whitesides, 2006]. Microfluidic systems step up in the area of drug delivery with 59 
promising features that allow control of particle size and stability of the final liposome product, 60 
during preparation with simple steps like applying different flow rate ratios (FRR) and total 61 
flow rate (TFR); Fig. 1.  62 
One of the aims of this study is to compare quality and properties of microfluidics formulations 63 
with liposomes generated through the hydration method in a previous study from our group 64 
[Briuglia et al., 2015].  In this current study, we changed the lipid:cholesterol ratio depending 65 
on the different applied FRR and TFR. The best formulation was chosen, and Atomic Force 66 
microscopy (AFM) studies were performed in order to evaluate liposome morphology. Finally, 67 
drug delivery studies with the same hydrophobic and hydrophilic drugs used by Briuglia et al. 68 
were encapsulated in order to investigate possible analogies or differences in terms of drug 69 
release. In our previous study, the most stable liposome composition was 2:1 as 70 
lipid:cholesterol ratio. The encapsulation efficacy was of 90% for atenolol (AT) and 88 % for 71 
quinine (Q) and the release profiles showed faster results for the hydrophilic molecule. In this 72 
paper, we compared hydration method with microfluidics formulation, and underline the 73 
benefits of microfluidics for industrial liposomes production. 74 
 75 
2. Materials and Methods 76 
2.1. Materials 77 
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The synthetic 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC) %) and 1,2-78 
distearoyl-sn-glycero-3- phosphocholine (DSPC) %) were a gift from Lipoid GmbH (Fig. 79 
2). Cholesterol (CH) , Tablets of phosphate-buffered saline (PBS, pH 7.4), atenolol 80 
(AT)  and quinine (Q)  were all obtained from Sigma-Aldrich. 81 
 82 
2.2. Preparation of liposomes 83 
Liposomes were prepared using a microfluidic micro-mixer, which through hydrodynamic 84 
flow enables nano precipitation of lipids. The system known as NanoAssemblrTM (Benchtop, 85 
Precision NanoSystems Inc., Vancouver, Canada) contains a microfluidic cartridge (52 mm 86 
thick and 36 mm height with moulded channels of 300 µm in width and 130 µm in height with 87 
staggered herringbone structures). The Nanoassemblr mixing chips have two stream inlets that 88 
merge into a micro-channel (Fig. 1). The two inlets used correspond to the lipid mixtures, 89 
which were dissolved in an organic solvent (ethanol), and the aqueous buffer (PBS, pH 7.4). 90 
Both fluids were pumped into the two inlets of the microfluidic micro-mixer using disposable 91 
syringes. The staggered herringbone structure of the micro-mixer enhances the advection and 92 
diffusion of the fluids flowing through the micro-channel [Belliveau et al., 2012]. By inducing 93 
rotational flow, the fluid streams get wrapped around each other, allowing the introduction of 94 
chaotic flow profile, that results in faster mixing of fluids [Belliveau et al., 2012]. The 95 
NanoAssemblrTM allowed the control of TFR (1, 6, 20 mL.ml-1) and the FRR (1:1, 3:1 and 5:1 96 
ratio of the aqueous: solvent) between the two inlet streams through computerised syringe 97 
pumps. An increase at FRR (e.g. 1:1 to 1:3 aqueous/ethanol) was reported to cause a decrease 98 
of mean size of liposomes along with the increase of polydispersity index (PDI) [Kastner et al., 99 
2014, 2015]$GGLWLRQDOO\7)5GLGQRWVKRZVLJQLILFDQWHIIHFWVRQWKHOLSRVRPHVL]H]HWDȗ100 
potential and polydispersity index (PDI) [Kastner et al., 2014, 2015]. 101 
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Two different ratios of lipid/cholesterol were used in the experiment, 1:1 and 2:1. For the 102 
encapsulation studies AT and Q were dissolved in PBS (at a concentration of 10 mg ml-1 for 103 
AT and 0.3 mg ml-1 Q). 104 
 105 
 106 
2.3 Stability Studies 107 
The stability tests were conducted for three weeks after the liposome formulations. The samples 108 
were divided into two batches and stored in controlled temperature rooms at 4°C and 37 °C. 109 
Size, PDI DQGȗ-potential were measured three times every week. Particles morphology was 110 
investigated using Atomic Force Microscopy (AFM) at week 0 for the four most stable 111 
formulations. 112 
 113 
2.4 Liposomes Physicochemical Characterisation 114 
2.4.1 Dynamic Light Scattering (DLS) 115 
The size distribution (mean diameter and PDI) of the liposomes was measured by dynamic 116 
light scattering (DLS) on a Zetasizer Nano-ZS (Malvern Instruments Ltd., UK), which enabled 117 
to obtain the mass distribution of particle size as well as the electrophoretic mobility. 118 
Measurements were made at 20 °C with a fixed angle of 137 ° in a dilution of 1/100 using PBS 119 
pH 7.4. Sizes quoted are the z-average mean (dz) for the liposomal hydrodynamic diameter 120 
(nm). Moreover, the same equipment was used to measure the ȗ-potential for all formulations. 121 
 122 
2.4.2 Fourier Transform Infrared Spectroscopy (FTIR) 123 
The characterisation of the liposome formulations using FTIR was performed in order to 124 
understand if the CH interaction with phospholipids was changed by the microfluidic method. 125 
The pellets formulations were scanned in an inert atmosphere over a wave number range of 126 
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3000-1500 cm-1 over 128 scans at a resolution of 4 cm-1 and an interval of 1 cm-1. All FT-IR 127 
spectra were recorder on BRUKER tensor II FT-IR Spectrometer and the background was 128 
subtracted from each spectrum.  129 
 130 
2.4.3 Atomic Force Microscopy (AFM) 131 
A volume of 5 µl from each formulation was placed on a freshly cleaved mica surface (1.5 cm 132 
x 1.5 cm; G250-0LFDVKHHWV´[´[´$JDU6FLHQWLILF/WG(VVH[8.7KHVDPSOH133 
was then air-dried for ~30 min and imaged at once by scanning the mica surface in air under 134 
ambient conditions using a Bruker MultiMode 8 Scanning Probe Microscope (Digital 135 
Instruments, Santa Barbara, CA, USA) operated on Peak Force QNM mode. The AFM 136 
measurements were obtained using ScanAsyst-air probes; the spring constant was calibrated 137 
by thermal tune (Nominal 0.4 N m-1) and the deflection sensitivity calibrated using a silica 138 
wafer. AFM scans were acquired at a resolution of 512 x 512 pixels at scan rate of 1 Hz, and 139 
produced topographic images of the samples in which the brightness of features increases as a 140 
function of height. AFM images were collected from random spot surface sampling.  141 
 142 
2.5 Dialysis dynamic experiment 143 
Dynamic dialysis is one of the most commonly used methods for the determination of release 144 
kinetics from nanoparticles [Modi and Anderson, 2013]. Prior to the addition of the mixture, 145 
the dialysis tube [cellulose membrane avg. flat width 10 mm (0.4 in.), Sigma] was placed in 146 
boiling water for 30 min and rinsed with a copious amount of water. Liposome mixtures were 147 
transferred to dialysis tubing and both ends were tied. This was added against 7 ml of PBS (pH 148 
7.4) [Kriwet and Müller-Goymann, 1995], for removal of non-encapsulated drug for 1 h.  149 
 150 
2.6 Drug release experiment 151 
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The 7 ml of PBS were removed and replace with fresh PBS and drug release profiles was 152 
analysed by extraction of 500 µL aliquots of the immersion medium at intervals of 30 min, 1, 153 
2, 3, 4, 15, 24, 48, 72 h and 8, 16 days at 37 oC. Each time the extracted volume was replaced 154 
with fresh PBS pre-equilibrated at 37°C making it possible to determine diffusion parameters. 155 
The amount of drug released at each time point was determined by UV-Vis using a Varian 50 156 
bio UV-visible spectrophotometer at room temperature. The concentration of the drug released 157 
from the dialysis tube was determined using a calibration curve of the pure drugs in PBS 158 
solutions at the wavelength where showed the maximum absorbance (AT - 275 nm [Lalitha et 159 
al., 2013] and Q ± 330 nm [Frosch et al., 2007]). The absorbance was converted into percentage 160 
release using a standard curve and experiments were performed in triplicates in order to ensure 161 
accuracy.  162 
 163 
2.7 Data fitting and Mathematical Model  164 
A previously studied mathematical model was used with the results obtained from this study 165 
[Peppas and Sahlin, 1989; Joguparthi et al., 2008]. The equation considered for the fitting 166 
model was:   167 ܯݐܯ ? ൌ ݇ ?Ǥ ݐ௠ ൅ ݇ ?ݐଶ௠ሺ ?ሻ 168 
where ݐ represents time, and ݇ ?, ݇ ? and ݉ are constants. ெ௧ெஶ represents the Fickian diffusional 169 
contribution considering the amount of drug released at time ݐ and infinite time. These 170 
parameters were used as the initial input in Igor Pro 6.34A in order to refine estimations using 171 
an optimization method. Several assumptions were made in order to obtain the mathematical 172 
model. Some of the assumptions were: the analysis of the data was based on one-dimensional 173 
diffusion; the suspended drug is in a fine state, so particles are much smaller in diameter than 174 
the thickness of the system; the diffusivity of the drug is constant; perfect sink conditions were 175 
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maintained during drug release experiment; the appearance of drug in the aqueous buffer is a 176 
result of the diffusion of the nanoparticles followed by diffusion across the dialysis membrane, 177 
although being generally treated as a first order process. 178 
 179 
2.7 Statistical analysis 180 
All experiments were performed in triplicates with calculation of means and standard 181 
deviations. Two-way analysis of variance (ANOVA) was used for multiple comparisons along 182 
ZLWK7XNH\¶VPXOWLSOHFRPSDULQJWHVW, followed by T-test to access statistical significance for 183 
paired comparisons. Significance was acknowledged for p values lower than 0.05. All 184 
calculations were made in GraphPad Prism version 6.0 (GraphPad Software Inc., La Jolla, CA).  185 
 186 
3. Results and Discussion 187 
3.1 Preparation of Liposomes at different FRR and TFR values 188 
Different TFR and FRR were investigated. Lower TFR and FRR produce larger liposomes 189 
(Fig. 3). The combination between the decrease of liposome size due to increase of FRR 190 
confirms previous studies in the literature [Jahn et al., 2010; Kastner et al., 2014, 2015]. 191 
Although no significant differences were detected in mean size distribution of particles 192 
manufactured from 1 to 6 and 6 to 20 ml min-1. Particles fabricated at 20 ml min-1 are smaller 193 
than the ones obtained at 1 ml min-1. Furthermore, particles formed with 1:1 lipid/cholesterol 194 
ratios were smaller. In Fig. 4 the distribution of particle sizes for different TFR and FRR can 195 
be observed. For example when comparing the DMPC and DSPC formulations prepared at 196 
FRR 1 of ~200 nm, sizes of 137 nm and 98 nm where obtained for formulations prepared from 197 
1:1 DMPC at TFR20 and FRR of 3:1 and 5:1 respectively. For 1:1 DSPC formulations prepared 198 
at TFR20 and FRR of 3:1 and 5:1 values of 85 nm and 76 nm respectively. This occurs since 199 
the fluid mixing is much faster, thus shear stress forces increase, which leads to the assembling 200 
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of smaller particles. Although some literature states that TFR does not significantly influence 201 
mean particle size [Jahn et al., 2007; Kastner et al., 2014, 2015], this study shows that TFR 202 
impact on particle size can be seen for higher values as 6 and 20 ml min-1. When comparing 203 
the formulations with different lipid to CH ratios, for both DMPC and DSPC 2:1 formulations 204 
(Fig. 3b and 3d) presented the higher size values, such as 729 nm for 2:1 DMPC TFR1 FRR 205 
3:1, 549 nm 2:1 DMPC TFR1 FRR 5:1, 1043 nm for 2:1 DSPC TFR1 FRR 3:1 and 375 nm for 206 
2:1 DSPC TFR1 FRR 5:1 (Fig. 3). Overall 1:1 liposome formulations for both DMPC and 207 
DSPC, presented lower mean size and lower PDI values. For the 1:1 DMPC and DSPC 208 
formulations, although differences in size were not significant, TFR of 6 and 20 mL ml-1, and 209 
FRR of 5:1 presented the smaller size vesicles. The size of liposomes produced out of 1:1 210 
lipid/cholesterol ratio ranged from ~70 nm to ~200 nm. The highest values of mean size are 211 
seen for 2:1 DMPC and 2:1 DSPC were the liposomes were formed at lower TFR (1) and FRR 212 
(3:1). When compared with our previous study [Briuglia et al., 2015], microfluidic allows the 213 
production of liposomes with smaller mean particle size by altering TFR and FRR. The zeta 214 
potential of the liposomes formed did not suffer significantly alterations despite differences in 215 
flow rates. Ratios with the liposomes had a negative zeta potential of around 0 and -10 mV.  216 
 217 
3.2 Effect of Manufacturing on stability and encapsulation efficacy 218 
According to our stability tests, following microfluidics procedure, the more stable liposomes 219 
result with 1:1 lipid/cholesterol ratio. This is the first major difference compared to our 220 
previous study [Briuglia et al., 2015], where the best formulation was 2:1. The formulations 221 
prepared at low TFR (1 ml min-1) present high standard deviations for the particle size 222 
distribution. Our results show that the more stable formulations were DMPC/CH 1:1 TFR20 223 
ml min-1 FR5:1, DMPC/CH 2:1 TFR6 ml min-1 5:1, DSPC/CH 1:1 TFR6 ml min-1 3:1, and 224 
DSPC/CH 2:1 TFR20 ml min-1 5:1. These results are accordingly to literature, which states that 225 
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a 50 % mol/mol ratio for lipid and cholesterol is ideal for liposome stability [Gregoriadis and 226 
Davis, 1979; Kirby et al., 1980]. Additionally, liposome formulations became more stable with 227 
the increase of TFR (6 and 20 ml ml-1) and with the increase of FRR (5:1). The graphs obtained 228 
from the stability studies of the most stable formulations can be found in Fig. 4. These were 229 
the ones used in further studies of AFM, IR, and drug release. 230 
Encapsulation efficiency (EE) values are very important as they give an insight on whether the 231 
production method can be applicable to the industrial background or not. EE data can be found 232 
on Table 1. Values of EE proved to be higher for ATL formulations. These results are in 233 
accordance to our previous study [Briuglia et al., 2015], where ATL showed overall  higher 234 
values of encapsulation efficiency than Q, even though they were produced by a different 235 
method. 236 
Hydrophilic and hydrophobic drugs will be loaded into the liposomes on different sites. 237 
Entrapment of hydrophilic molecules occurs in the aqueous compartments of the vesicle while 238 
hydrophobic drugs have higher affinity to the lipid bilayers of the vesicle [Kulkarni et al., 239 
1995]. Hydrophilic encapsulation for example is also influenced by liposome size, being that 240 
encapsulation efficiencies achieved are higher for large unilamellar vesicles. Additionally, 241 
charged vesicles improve hydrophilic loading [Kulkarni et al., 1995].  Although loading values 242 
of  hydrophobic molecules are not majorly affected by liposome size, and multilamellar 243 
vesicles seem to be the most suitable [Kulkarni et al., 1995]. Furthermore, the characteristics 244 
of lipids used during manufacturing and presence of cholesterol are key players for 245 
hydrophobic encapsulation [Kulkarni et al., 1995]. Higher CH concentrations will have a 246 
decreasing effect on membrane permeability. Hydrophobic loading will be highly dependent 247 
on lipid bilayer characteristics, and higher results seem to be achieved for fluid membranes 248 
[Kulkarni et al., 1995]. Furthermore, CH seems to present a competitive action with the 249 
hydrophobic drug during the assembly and encapsulation for packing space in the lipid bilayer 250 
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[Ali et al., 2010]. Formulations that present lower CH contents were expected to show better 251 
encapsulation efficacy. This did not occur for the incorporation of quinine in the 2:1 DMPC 252 
formulation prepared at TFR 6 ml ml-1 FR 5:1 when compared to 1:1 DMPC prepared at TFR 253 
20 ml ml-1 and FRR of 5:1. This may indicate that a higher mixing rate could cause better 254 
encapsulation. Studies show that liposome size, and lipid size and composition, play a crucial 255 
part in dictating drug release profiles and encapsulation efficiency [Betageri and Parsons, 256 
1992]. Manufacturing methods may also influence EE [Kulkarni et al., 1995]. EE values of the 257 
two drugs were very similar to our previous study where film hydration method was used 258 
[Briuglia et al., 2015]. In general, the results obtained from this study indicate that the 259 
microfluidic manufacturing process allows for high EE results of ~100 % for ATL and of ~70 260 
% for Q. Also, this study shows that microfluidic technique is a faster method of encapsulating 261 
drugs into liposomal products. This was to be expected since recent studies [Kastner et al., 262 
2014, 2015], also using the Nanoassemblr, describe the ability of merging liposome 263 
manufacturing and drug encapsulation in a single process step, as well as flexibility and ease 264 
of applying lab-on-a-chip technique. These characteristics would have great impact in industry 265 
[Kastner et al., 2014, 2015].  266 
 267 
3.3 AFM 268 
Atomic force microscopy is a fast and easy to perform method, which allows to evaluate 269 
liposomes morphology. The most stable formulations that were mentioned in the previous 270 
section (DMPC/CH 1:1 TFR20 ml min-1 FR5:1, DMPC/CH 2:1 TFR6 ml min-1 5:1, DSPC/CH 271 
1:1 TFR6 ml min-13:1, and DSPC/CH 2:1 TFR20 ml min-1 5:1) were used for the AFM studies. 272 
AFM results are presented in figure 5.  273 
The diameter acquired by AFM measurements is comparable to DLS acquired data, where 274 
some differences can be spotted. The liposomes present sizes of around 200-300 nm among 275 
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the different formulations which can be seen in Table 2. Differences can be seen when 276 
compared with DLS size results. Reasoning behind these can be liposomes composition 277 
between formulations, causing changes in the structures left after they dry and collapse on the 278 
mica surface, and also deformations caused by the tip of AFM probe [Ruozi et al., 2007].  279 
Despite this, results obtained are concordant with literature that describes liposome images as 280 
asymmetrical flattened structures described as planar vesicles [Ruozi et al., 2007]. These are 281 
also according to our previous study, where presence of cholesterol improved the shape of 282 
liposomes by stabilizing them [Briuglia et al., 2015]. 283 
 284 
3.4 FT-IR 285 
IR spectroscopy is a complex method, which is especially useful since the resulting spectrum 286 
acts as a fingerprint for compounds. This analysis was performed on the four formulations that 287 
were the most stable (DMPC/CH 1:1 TFR20 ml min-1 FR5:1, DMPC/CH 2:1 TFR6 ml min-1 288 
5:1, DSPC/CH 1:1 TFR6 ml min-13:1, and DSPC/CH 2:1 TFR20 ml min-1 5:1). Medium 289 
intensity bands near 3000 cm-1 DMPC and DSPC spectrum represent C-H single-bond 290 
stretching motions (Fig. 6). C-H scissoring or bend can be seen at 1330-1500 cm-1. The other 291 
important bond present occurs at 1680 to 1750 cm-1 and represents the carbonyl group of the 292 
ester bond [Larkin, 2011]. The IR spectrum of the different ratios of lipids and CH can be seen 293 
in Fig. 3. The major difference between both DMPC and DSPC spectrum, comparing the 294 
different ratios, is the intensity of the peaks. The spectrums of the 2:1 lipid ratios show strongest 295 
peaks. When CH is present at higher concentrations, as it happens in the 1:1 formulation, it 296 
interacts with the phospholipids provoking steric hindrance that ultimately results in weaker 297 
peaks. This is more noticeable in the DMPC spectrums. Such results are in accordance to our 298 
previous results [Briuglia et al., 2015], using the film hydration method. This indicates that the 299 
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microfluidic technique does not alter the composition of the lipids not the way in which CH 300 
interacts with the phospholipids. 301 
3.5 Drug release 302 
Drug release studies are mainly influenced by liposome size, lipid composition, and lipids chain 303 
length. The drug release profile will depend on where the drug is accommodated within the 304 
liposome. A hydrophilic drug will be dissolved in the aqueous space inside the vesicles and 305 
hydrophobic compounds are accommodated within the lipid bilayer. Q and AT drug release 306 
profile graph can be seen in Fig. 7. According with literature [Hua, 2014], all of the different 307 
formulations showed an initial burst of drug release. AT showed similar release profiles for the 308 
different formulations. In our previous paper, each time liposomes were formulated by 309 
hydration method, AT release resulted in faster release than Q.  310 
In this study, there is not a distinct behaviour between AT and Q.  AT presents a faster release 311 
profile for DMPC formulations. On the contrary, Q shows a faster release for DSPC 312 
formulations, especially for 1:1 DSPC that was prepared at TFR of 20 ml min-1 and FRR 5:1. 313 
This may be related to the fact that DSPC has an increased lipid chain length, and there seems 314 
to be a tendency for an increase of loading and encapsulation efficiency with increasing lipid 315 
chain length [Mohammed et al., 2004]. Furthermore, different values of TFR and FRR can 316 
form liposomes slightly different structured compared to the formulations through film 317 
hydration method. For example, if the liposomes produced with microfluidics are unilamellar 318 
vesicles, this leads to higher stability and encapsulation of hydrophilic vesicles. Consequently, 319 
release profile of ATL would be slower. Since hydrophobic molecules have higher affinity for 320 
multilamellar vesicles, Q encapsulation values achieved would be lower, ultimately leading to 321 
a faster release of the drug. 322 
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Formulations which contained 2:1 lipid/cholesterol contents, presented faster release profiles 323 
with higher maximum releases, when compared with formulations with 1:1 lipid/cholesterol 324 
ratio. According to previous studies with hydrophobic drugs, higher retention rates are seen 325 
with the increase of CH content in the formulation. As CH is present in increasing contents, it 326 
stabilizes liposomes but it obstructs the leakage of hydrophobic drugs [Ali et al., 2010]. Despite 327 
this, 1:1 DSPC formulation encapsulated with Q, showed the fastest release.  328 
From these results, we can see that microfluidic manufacturing may alter the way drugs are 329 
loaded within the liposomes formed, ultimately causing changes in release profile of a specific 330 
drug. This method allows different outcome possibilities accordingly to the lipid and drug in 331 
question. When comparing these results with our previous study, we can see that altering 332 
microfluidic parameters influences the drugs interaction with the liposomes, making it possible 333 
to achieve faster release profiles for Q. 334 
The developed fitting model, based on Eq. 1, can be seen in Fig. 8 and values for the constants 335 
of ݇ ?, ݇ ? and ݉ can be found in Table 3. From Fig. 8, a good correlation between drug release 336 
profiles obtained in this study and the predicted values can be observed. These results validate 337 
the obtained mathematical model.  338 
4. Conclusions 339 
In this study, we showed the applicability of microfluidic manufacturing method as a simpler 340 
and faster way for liposomes production. Liposomes can be adjusted and manipulated by 341 
changing different parameters during assembly, such as TFR and FRR. It is possible to obtain 342 
smaller and more stable liposomes increasing or reducing the TFR or the FRR. The versatility 343 
of microfluidic is very promising and it provides a suitable alternative method to film 344 
hydration. Microfluidic simplifies the encapsulation step, without losing encapsulation 345 
efficiency, making it much faster than traditional manufacturing methods. Moreover, by 346 
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microfluidics, the scale-up for particle production will be possible by manufacturing a scale-347 
up system that can be mainly used for clinical-size batches, with all-in-one scale-up system and 348 
not by having multiple steps as in film hydration method. However, the production of large 349 
scale (industrial) materials using current microfluidic technologies can be a challenge (Carugo 350 
et al., 2016). 351 
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Figures legend: 432 
Fig.   1   Representation of microfluidic chip for Nanoassemblr. 433 
Fig. 2 Chemical structures of the compounds used: (a) 2-dimyristoyl-sn-glycero-3-434 
phosphocholine (DMPC), (b) cholesterol (CH), (c) 1,2-distearoyl-sn-glycero-3-435 
phosphocholine (DSPC), (d) atenolol (ATL) and (e) quinine (Q). 436 
Fig. 3 Average particle size of all the formulations under different TFR and FRR, (a) 437 
DMPC/CH 1:1 , (b) DMPC/CH 2:1, (c)  DSPC/CH 1:1, and (d)  DSPC/CH 2:1ZKHUHS438 
comparing with week 1;** - SFRPSDULQJZLWKZHHN- SFRPSDULQJZLWK439 
week 1;**** - SFRPSDULQJZLWKZHHN- SFRPSDULQJZLWK week 2; ## - p 440 
FRPSDULQJZLWKZHHN- SFRPSDULQJZLWKZHHN- S441 
comparing with week 2; + - SFRPSDULQJZLWKZHHN- SFRPSDULQJZLWK442 
week 3; +++ - SFRPSDULQJZLWKZHHN- p comparing with week 3. 443 
Fig. 4 Average particle size of the most stable formulations from week 1 to week 3 (* - S444 
0.05 comparing with TFR1 FRR 3:1;** - SFRPSDULQJZLWK7)5)55- S445 
comparing with TFR1 FRR 3:1;**** - SFRPSDULQJwith TFR1 FRR 3:1; # - S446 
comparing with TFR1 FRR 5:1; ## - SFRPSDULQJZLWK7)5)55- S447 
comparing with TFR1 FRR 5:1; #### - SFRPSDULQJZLWK7)5)55- S448 
comparing with TFR6 FRR 3:1; ºº - SFRPSaring with TFR6 FRR 3:1; ººº - S449 
comparing with TFR6 FRR 3:1; ºººº - SFRPSDULQJZLWK7)5)55µ- S450 
FRPSDULQJZLWK7)5)55µ¶- SFRPSDULQJZLWK7)5)55µ¶¶- S451 
FRPSDULQJZLWK7)5)55µ¶¶¶- p FRPSDULQJZLWK7)5)55[- S452 
comparing with TFR20 FRR 3:1; xx - SFRPSDULQJZLWK7)5)55[[[- S453 
0.001 comparing with TFR20 FRR 3:1; xxxx - SFRPSDULQJZLWK7)5)55454 
red lines represent results at 4ºC and blue dotted lines represent results at 37ºC. 455 
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Fig. 5 FTIR spectra of (a) DMPC/CH 1:1 TFR20 ml min-1 FR5:1, (b) DMPC/CH 2:1 TFR6 ml 456 
min-1 5:1, (c) DSPC/CH 1:1 TFR6 ml min-1 3:1, and (d)  DSPC/CH 2:1 TFR20 ml min-1 5:1 457 
Fig. 6 AFM images of (a) DMPC/CH 1:1 TFR20 ml min-1 FR5:1, (b) DMPC/CH 2:1 TFR6 ml 458 
min-1 5:1, (c)DSPC/CH 1:1 TFR6 ml min-13:1, and (d) DSPC/CH 2:1 TFR20 ml min-1 5:1 459 
Fig. 7 Drug release graphs of (a) quinine, and (b) atenolol. 460 
Fig. 8 Fitting model obtained from drug release data of (a) quinine, and (b) atenolol. 461 
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Table 1.  462 
Lipid/cholesterol ratio TFR FR Atenolol (%EE) Quinine (%EE) 


















Table 1 shows results of Encapsulation Efficiency (%EE) for Atenolol and Quinine using the 465 
best formulations obtained from previous experiences.  466 
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Table 2. 467 
Lipid/cholesterol 
ratio 
TFR FR Size/nm 
DMPC 1:1 20 5:1 363.67± 39.78 
 
DMPC 2:1 6 5:1 217.83± 18.33 
 
DSPC 1:1 6 3:1 251.83± 46.55 
 
DSPC 2:1 20 5:1 266.83± 48.43 
 468 
Description: 469 
Table 2 shows liposome sizes for AFM images.  470 
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Table 3. 471 
FITTING MODEL 472 
(a) 473 
(a) 1:1 DMPC TFR20 FRR 
5:1 Atenolol 
2:1 DMPC TFR6 FRR 5:1 
Atenolol 
1:1 DSPC TFR6 FRR 3:1 
Atenolol 
2:1 DSPC TFR20 FRR 
5:1 Atenolol 
k1 10.832 ± 0.973 15.528 ± 1.45 14.883 ± 1.23 12.747 ± 0.885 
k2 -0.51233 ± 0.995 -0.91178 ± 0.713 -1.1181 ± 0.185 -0.24065 ± 1.01 
m 0.21311 ± 0.0669 0.24234 ± 0.0599 0.30372 ± 0.0297 0.23711 ± 0.056 
     
(b)     
k1 2.4543 ± 0.614 11.748 ± 2.12 12.507 ± 1.9 9.9142 ± 1.91 
k2 -0.094561 ± 0.0492 -0.73843 ± 0.288 -0.48886 ± 0.152 -0.3902 ± 0.156 
m 0.45703 ± 0.0666 0.3952 ± 0.0481 0.44776 ± 0.0413 0.45255 ± 0.0515 
 474 
Description: 475 
Table 2 Values of the fitting constants: ݇ ?, ݇ ? and ݉ for (a) atenolol and (b) quinine. 476 
  477 
International Journal of Pharmaceutics 
25 
Guimarães et al., 2016 
Figure 1. 478 
 479 
  480 
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Figure 2. 481 
 482 
  483 
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Figure 3. 484 
 485 
  486 
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Figure 4. 487 
 488 
 489 
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Figure 5. 490 
 491 
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Figure 6. 493 
 494 
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Figure 7. 496 
 497 
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Figure 8. 499 
 500 
 501 
